BC Week In Review | Mar 17, 2017
Company News

Shionogi, Duchesnay deal

Shionogi granted Duchesnay exclusive, U.S. and Canadian rights to develop and commercialize dyspareunia drug Osphena ospemifene. Shionogi will receive quarterly minimum payments for eight years and is eligible for undisclosed milestones. Osphena, a selective estrogen...
BC Innovations | Jun 23, 2016
Distillery Therapeutics

Therapeutics: Thyroid hormone receptor

Hepatic disease INDICATION: Scleroderma; liver fibrosis Mouse studies suggest agonizing thyroid hormone receptor could help treat liver fibrosis and scleroderma-associated fibrosis. In a mouse model of liver fibrosis, the endogenous thyroid hormone receptor agonist triiodothyronine...
BC Week In Review | Dec 14, 2015
Clinical News

Ospemifene: Phase III started

Shionogi began a double-blind, placebo-controlled, U.S. Phase III trial to evaluate 60 mg oral Osphena once daily in about 600 patients. Osphena is approved in the U.S. to treat dyspareunia due to menopause. Shionogi has...
BioCentury | Jan 12, 2015
Finance

Buyside view XXIII: Milestones galore

Stephen Hansen, Associate Editor and Jennifer Rhodes, Staff Writer   Buyside view XXIII The maturation of the biotech sector over the past few years finds fund managers focusing on a slew of clinical milestones and...
BC Week In Review | Oct 27, 2014
Company News

Forendo Pharma, Apricus Biosciences deal

Forendo granted Apricus exclusive, U.S. rights to develop and commercialize fispemifene , which has completed two Phase II trials for male secondary hypogonadism. Forendo received an upfront license fee of $12.5 million, consisting of $5 million...
BC Extra | Oct 23, 2014
Financial News

Forendo closes EUR 12M series A

Forendo Pharma Oy (Turku, Finland) closed a EUR 12 million ($15.3 million) series A round led by new investors Novartis Venture Fund and MS Ventures. Existing investors including Karolinska Development AB ; Novo Seeds; and...
BioCentury | Jan 13, 2014
Finance

Buyside View XXII: 'Grown up' means growth

Stephen Hansen Senior Writer  An increase in regulatory approvals and new breakthrough therapies has money managers buying into the concept that biotech has entered a new product cycle that provides a strong fundamental basis for...
BioCentury | Oct 14, 2013
Emerging Company Profile

Forendo: Fixing endometriosis

Forendo Pharma Oy is developing inhibitors of hydroxysteroid 17-beta dehydrogenase 1 to treat endometriosis without depleting circulating estrogen, thus avoiding side effects of available therapies. In endometriosis, tissue similar to endometrium in the uterus grows...
BC Week In Review | May 13, 2013
Company News

Shionogi sales and marketing update

Shionogi launched Osphena ospemifene in the U.S. to treat moderate to severe dyspareunia due to postmenopausal vulvovaginal atrophy. The wholesale acquisition cost is $158 for 30 once-daily tablets. FDA approved the selective estrogen receptor modulator...
BC Week In Review | Apr 1, 2013
Clinical News

Ospemifene regulatory update

Shionogi said EMA accepted for review an MAA for ospemifene to treat postmenopausal vulvovaginal atrophy. In February, FDA approved ospemifene as Osphena to treat moderate to severe dyspareunia due to postmenopausal vulvovaginal atrophy (see BioCentury,...
Items per page:
1 - 10 of 88
BC Week In Review | Mar 17, 2017
Company News

Shionogi, Duchesnay deal

Shionogi granted Duchesnay exclusive, U.S. and Canadian rights to develop and commercialize dyspareunia drug Osphena ospemifene. Shionogi will receive quarterly minimum payments for eight years and is eligible for undisclosed milestones. Osphena, a selective estrogen...
BC Innovations | Jun 23, 2016
Distillery Therapeutics

Therapeutics: Thyroid hormone receptor

Hepatic disease INDICATION: Scleroderma; liver fibrosis Mouse studies suggest agonizing thyroid hormone receptor could help treat liver fibrosis and scleroderma-associated fibrosis. In a mouse model of liver fibrosis, the endogenous thyroid hormone receptor agonist triiodothyronine...
BC Week In Review | Dec 14, 2015
Clinical News

Ospemifene: Phase III started

Shionogi began a double-blind, placebo-controlled, U.S. Phase III trial to evaluate 60 mg oral Osphena once daily in about 600 patients. Osphena is approved in the U.S. to treat dyspareunia due to menopause. Shionogi has...
BioCentury | Jan 12, 2015
Finance

Buyside view XXIII: Milestones galore

Stephen Hansen, Associate Editor and Jennifer Rhodes, Staff Writer   Buyside view XXIII The maturation of the biotech sector over the past few years finds fund managers focusing on a slew of clinical milestones and...
BC Week In Review | Oct 27, 2014
Company News

Forendo Pharma, Apricus Biosciences deal

Forendo granted Apricus exclusive, U.S. rights to develop and commercialize fispemifene , which has completed two Phase II trials for male secondary hypogonadism. Forendo received an upfront license fee of $12.5 million, consisting of $5 million...
BC Extra | Oct 23, 2014
Financial News

Forendo closes EUR 12M series A

Forendo Pharma Oy (Turku, Finland) closed a EUR 12 million ($15.3 million) series A round led by new investors Novartis Venture Fund and MS Ventures. Existing investors including Karolinska Development AB ; Novo Seeds; and...
BioCentury | Jan 13, 2014
Finance

Buyside View XXII: 'Grown up' means growth

Stephen Hansen Senior Writer  An increase in regulatory approvals and new breakthrough therapies has money managers buying into the concept that biotech has entered a new product cycle that provides a strong fundamental basis for...
BioCentury | Oct 14, 2013
Emerging Company Profile

Forendo: Fixing endometriosis

Forendo Pharma Oy is developing inhibitors of hydroxysteroid 17-beta dehydrogenase 1 to treat endometriosis without depleting circulating estrogen, thus avoiding side effects of available therapies. In endometriosis, tissue similar to endometrium in the uterus grows...
BC Week In Review | May 13, 2013
Company News

Shionogi sales and marketing update

Shionogi launched Osphena ospemifene in the U.S. to treat moderate to severe dyspareunia due to postmenopausal vulvovaginal atrophy. The wholesale acquisition cost is $158 for 30 once-daily tablets. FDA approved the selective estrogen receptor modulator...
BC Week In Review | Apr 1, 2013
Clinical News

Ospemifene regulatory update

Shionogi said EMA accepted for review an MAA for ospemifene to treat postmenopausal vulvovaginal atrophy. In February, FDA approved ospemifene as Osphena to treat moderate to severe dyspareunia due to postmenopausal vulvovaginal atrophy (see BioCentury,...
Items per page:
1 - 10 of 88